First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    ENDRA Life Sciences Inc.

    NDRA · 3 developments mapped · last assessed 2026-08-21

    Market Ontology has mapped 3 macro, policy, and market developments to ENDRA Life Sciences Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for NDRA yet, so no modelled value is shown. The NDRA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run NDRA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for NDRA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc.

      Direct impact from acquisition premium and increased certainty of value realization for shareholders.

      · Moves implied acquisition price per share, probability of deal completion

    • Open question

      ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.

      Direct impact from acquiring a new business (Renergen) and a complete strategic pivot. This will fundamentally change NDRA's business model, revenue streams, and risk profile.

      · Moves future growth rate of the combined helium business, cost of capital for the new business model, synergy realization from the merger

    What changed, by assumption

    Future growth rate of the combined helium business
    • 2026-08-21ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.
    Implied acquisition price per share
    • 2026-08-21ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc.
    Business model and industry classification change
    • 2026-08-17ENDRA Life Sciences Inc. to Acquire Noble Africa LLC

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-07-22Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-07-22Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-06-25Valuation multipleBullishTarget re-rates to bid premium until close.0.70
    2026-06-25Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-06-25Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-06-25RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-21ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.mixed3-12m0.80
    2026-08-21ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc.Bullishintraday0.80
    2026-08-17ENDRA Life Sciences Inc. to Acquire Noble Africa LLCmixed1-3m0.80